Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,147,286.92 in Stock

Posted by Hanz Christensen on Dec 3rd, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.98, for a total value of $1,147,286.92. Following the completion of the transaction, the insider owned 13,728,924 shares in the company, valued at approximately $82,098,965.52. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

On Friday, November 28th, Endurance (Cayman) Ltd Svf sold 61,493 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.44, for a total transaction of $396,014.92.
On Wednesday, November 26th, Endurance (Cayman) Ltd Svf sold 127,938 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.39, for a total transaction of $817,523.82.
On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.38, for a total transaction of $1,505,494.98.
On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total transaction of $1,400,988.45.
On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total transaction of $649.00.
On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.50, for a total value of $158,944.50.
On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $401,738.15.
On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total value of $278,308.16.
On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.99, for a total value of $924,754.17.
On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $887,235.90.

Vir Biotechnology Stock Up 11.4%

NASDAQ VIR traded up $0.64 on Wednesday, reaching $6.27. The company had a trading volume of 2,383,912 shares, compared to its average volume of 1,552,520. The company’s fifty day moving average is $5.78 and its 200 day moving average is $5.33. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The stock has a market capitalization of $872.28 million, a P/E ratio of -1.74 and a beta of 1.34.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $1.98 million. During the same period in the prior year, the firm earned ($1.56) earnings per share. Vir Biotechnology’s revenue was up .8% compared to the same quarter last year. On average, research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on VIR shares. Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Evercore ISI initiated coverage on Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vir Biotechnology in a report on Monday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.30.

View Our Latest Analysis on VIR

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently modified their holdings of the stock. Cinctive Capital Management LP purchased a new stake in Vir Biotechnology in the first quarter worth $547,000. Clarius Group LLC grew its stake in shares of Vir Biotechnology by 979.7% during the 2nd quarter. Clarius Group LLC now owns 617,535 shares of the company’s stock worth $3,112,000 after acquiring an additional 560,342 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Vir Biotechnology by 43.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after acquiring an additional 225,544 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Vir Biotechnology in the 2nd quarter worth about $289,000. Finally, Allianz Asset Management GmbH raised its stake in Vir Biotechnology by 6.2% in the 2nd quarter. Allianz Asset Management GmbH now owns 327,700 shares of the company’s stock valued at $1,652,000 after acquiring an additional 19,000 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

(Get Free Report)

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).